Genetic Testing to Study Gallbladder Cancer and Treatment Response
Uses gene sequencing on tumors to study gallbladder cancer and treatment response.
Plain-language title generated from the registry record
Registry title: NGS in Gallbladder Cancer and Response to Treatment
Key facts
- Where
- Varanasi, IndiaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT05404347, who can take part
Where in India
- Banaras Hindu UniversityVaranasi, IndiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Banaras Hindu University
- Trial code
- NCT05404347
- Record updated
- 13 August 2024
- Original description
Evidence suggests distinct models of molecular and pathologic progression, and a growing body of genetics data points to a heterogeneous collection of underlying mutations in key oncogenes and tumor suppressor genes. Although tumor genetics have been used to tailor individual treatment regimens and guide clinical decision making in other cancers, these principles have not been applied in gallbladder malignancy. Recent clinical trials with targeted therapies seem promising, although the relationships between subsets of patients with positive responses to therapy and tumor genetics remain unexplored.Read full original descriptionShow less
Genetic Mutations and Response to Treatment in Gallbladder Cancer: A Hospital Based Cohort Study
Evidence suggests distinct models of molecular and pathologic progression, and a growing body of genetics data points to a heterogeneous collection of underlying mutations in key oncogenes and tumor suppressor genes. Although tumor genetics have been used to tailor individual treatment regimens and guide clinical decision making in other cancers, these principles have not been applied in gallbladder malignancy. Recent clinical trials with targeted therapies seem promising, although the relationships between subsets of patients with positive responses to therapy and tumor genetics remain unexplored.
Inclusion: Treatment naïve patients with histologically proven carcinoma of the gallbladder.
Exclusion: No histological evidence of malignancy; Pregnant and lactating women.